Search results for: Generics
Filter search results
HTA and Payment Mechanisms for New Drugs to Tackle AMR
1 September 2019
Antimicrobial resistance (AMR) is a growing public health threat, limiting the ability of health care systems to prevent and treat infections and save lives. In parallel, global antibiotic development pipelines…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Assessing the entire life-cycle of SGA, the study explores how…
Making Outcome-Based Payment a Reality in the NHS
2 January 2019
This report explores the feasibility of introducing one type of flexible payment mechanism – outcome-based payment (OBP) – for cancer medicines into the NHS in England. OBP could help to…
Additional Elements of Value for Health Technology Assessment Decisions
1 May 2017
Antimicrobial resistance (AMR) occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that render the medications used to cure the infections they cause ineffective. Antimicrobial resistance…
Incentives for New Drugs to Tackle Anti-Microbial Resistance
1 May 2017
Resistance to antibiotics is growing, posing a major health risk in rich and poor countries. Additional ways of rewarding R&D are required. Mechanisms designed to encourage companies to undertake R&D…
Anaesthesia
1 February 1976
Anaesthesia is the art or science of rendering the patient unaware, thereby providing an indispensable foundation for surgery. Although man had unsuccessfully been attempting to eliminate the pain of surgical…
New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
1 October 2010
Antimicrobial resistance (AMR) to drugs, a natural and unavoidable consequence of treating infectious diseases, is a growing global public health threat. The EU Commission is to develop comprehensive proposals by…
Incentives for R&D for New Antimicrobial Drugs
1 April 2011
Antimicrobial resistance (AMR) is becoming a major global public health threat and has begun to command attention from European and US policy makers. An initial focus on monitoring AMR and…
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
1 April 2011
Antimicrobial resistance (AMR) to drugs is a natural and unavoidable consequence of treating infectious diseases. A growing global public health threat, AMR reduces the chances of successfully treating patients with…